Single-agent rituximab provides extended remission in follicular lymphoma

Results of the Swiss Group for Clinical Cancer Research (SAKK) Trial 35/98 have been published, and the results indicate potential extra benefits to long-term single-agent rituximab in certain patients with follicular lymphoma, suggesting that some patients may not need rituximab plus combination chemotherapy.

Researchers tested the efficacy of rituxumab in 4 weeks of induction therapy followed by bi-monthly infusions over the next eight months in previously untreated FL patients. At week 12 the subjects were randomized to receive either no further therapy or the extended protocol.

Eight years later, 45% of patients previously untreated who had been randomized to receive the extended protocol after responding to induction therapy were event-free. This, compared to just 22% in the other arm.

At a median follow-up of 9.5 years, the median event-free survival for patients who received no additional therapy was 13 months, compared to 24 months in patients receiving the extended protocol.

Although there was a clear benefit seen in event-free survival times, this did not extend into overall mortality, at least not in a statistically significant way.

Follicular lymphoma

Immunotherapy maintenance

The Journal of Clinical Oncology



The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.